ABSCI CORPORATION ABSI 深 沪
已收盘 12-12 16:00:00 美东时间
3.64
-0.200
-5.21%
华盛通- 最 高3.83
- 今 开3.83
- 成交量 487.71万股
- 最 低 3.50
- 昨 收 3.84
- 总市值 5.46亿
- 52周最高 6.33
- 市盈率 静 --
- 换手率 3.25%
- 52周最低 2.01
- 委 比 -30.03%
- 总股本 1.50亿
- 历史最高 31.53
- 量 比 1.18
- 振 幅 8.59%
- 历史最低 1.1111
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Needham Reiterates Buy on Absci, Maintains $7 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.
12-12 19:41
Absci Unveils Preclinical Data Showing AI‑Designed Antibody ABS‑201 Stimulates Hair Growth; Findings Presented At ABS‑201 KOL Seminar
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivoHuman ex vivo data validate ABS-201's potential to reverse follicular miniaturization and
12-11 21:15
Absci Doses Participants In Phase 1/2a HEADLINE Trial Of ABS-201
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in the Phase 1/2a
12-04 21:07
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
11-13 20:06
Needham Maintains Buy on Absci, Lowers Price Target to $7
Needham analyst Gil Blum maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $8 to $7.
11-13 18:46
Absci shares are trading lower after the company reported mixed Q3 financial results.
Absci shares are trading lower after the company reported mixed Q3 financial re...
11-13 05:17
Absci Q3 EPS $(0.20) Beats $(0.21) Estimate, Sales $378.000K Miss $1.644M Estimate
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 5.66 percent. This is a 16.67 percent increase over losses of $(0.24) per share from the same
11-13 05:09
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Absci climbs on clinical trial acceleration
Absci (NASDAQ:ABSI) shares soared ~18% on Wednesday after the AI-focused biotech announced a faster timeline to begin a proof-of-concept trial for ABS-201, an experimental therapy for an inherited for...
10-15 23:31
